Results 21 to 30 of about 4,502 (202)

Aprepitant, an antiemetic agent, interferes with metal ion homeostasis of Candida auris and displays potent synergistic interactions with azole drugs

Virulence, 2020
With the rapid increase in the frequency of azole-resistant species, combination therapy appears to be a promising tool to augment the antifungal activity of azole drugs against resistant Candida species.
Hassan E. Eldesouky, Nadia A. Lanman, Tony R. Hazbun, Mohamed N. Seleem   +3 more
doaj   +1 more source

Effects of aprepitant on post-operative nausea and vomiting in patients with congenital heart disease undergoing cardiac surgery or catheterization procedures: a retrospective study with subjects as their own historical control

Frontiers in Anesthesiology, 2023
IntroductionFor patients undergoing cardiac surgery and catheterization procedures, severe post-operative nausea and vomiting (PONV) can occur despite standard anti-emetic interventions.
John W. Belk, Mark D. Twite, Katherine S. Klockau, Lori J. Silveira, Rachel G. Clopton   +4 more
doaj   +1 more source

Aprepitant [PDF]

pharma-kritik, 2004
In Kombination mit anderen hochwirksamen Antiemetika kann Aprepitant bei einer stark emetogenen Chemotherapie, besonders bei der Verabreichung von Cisplatin, Brechreiz und Erbrechen verhüten helfen.
openaire   +1 more source

The SP/NK1R System-Mediated ROS Generation in GBM Cells through Inhibiting Glutaredoxin Protein

Neurology Research International, 2021
Altered redox balance is among the main contributing factors developing glioblastoma multiforme (GBM), a highly aggressive grade IV brain tumor. Neuropeptide substance P (SP) plays a key role in modifying the cellular redox environment by activating the ...
Negeen Mehrabani, Mohammad Reza Vaezi Kakhki, Hossein Javid, Safieh Ebrahimi, Seyed Isaac Hashemy   +4 more
doaj   +1 more source

Human substance P receptor binding mode of the antagonist drug aprepitant by NMR and crystallography

Nature Communications, 2019
The FDA approved drug aprepitant is an antagonist of the Neurokinin 1 receptor (NK1R). Here the authors present aprepitant bound NK1R crystal structures and use NMR spectroscopy to gain further insights into the dynamics of aprepitant binding, which is ...
Shuanghong Chen, Mengjie Lu, Dongsheng Liu, Lingyun Yang, Cuiying Yi, Limin Ma, Hui Zhang, Qing Liu, Thomas M. Frimurer, Ming-Wei Wang, Thue W. Schwartz, Raymond C. Stevens, Beili Wu, Kurt Wüthrich, Qiang Zhao   +14 more
doaj   +1 more source

Identification of optimal contemporary antiemetic prophylaxis for doxorubicin-cyclophosphamide chemotherapy in Chinese cancer patients: post-hoc analysis of 3 prospective studies

Cancer Biology & Medicine, 2021
Objective: Chemotherapy-induced nausea and vomiting (CINV) are common with doxorubicin-cyclophosphamide (AC) chemotherapy. Recommended antiemetic regimens incorporate neurokinin-1 receptor antagonist (NK1RA), 5-hydroxytryptamine type-3 receptor ...
Winnie Yeo, Leung Li, Thomas KH Lau, Kwai T Lai, Vicky TC Chan, Kwan H Wong, Christopher CH Yip, Elizabeth Pang, Maggie Cheung, Vivian Chan, Carol CH Kwok, Joyce JS Suen, Frankie KF Mo   +12 more
doaj   +1 more source

Cardioprotective action of aprepitant in a rat model of ischemia-reperfusioninduced myocardial injury: role of PI3K-AkT-GSK-3β-HIF-1α signaling pathway

Acta Cirúrgica Brasileira, 2022
Purpose: The present study explored the role and mechanism involved in aprepitant-induced cardioprotective effects in rat model of ischemia-reperfusion injury.
Mei Qian, Yang Liu
doaj   +1 more source

Effect of Aprepitant on Chemotherapy-induced Adverse Reactions in Gynecological Malignancy Patients

Zhongliu Fangzhi Yanjiu, 2018
Objective To observe the curative effect of aprepitant on chemotherapy-induced nausea and vomiting(CINV) and hemoglobin level in gynecological malignancy patients.
HE Yang, YANG Runfeng, ZHOU Yingying, XU Qian, YAN Hao, JIANG Lei, JIANG Xiaohui, HUANG Yi   +7 more
doaj   +1 more source

Single‐dose NEPA versus an aprepitant regimen for prevention of chemotherapy‐induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy

Cancer Medicine, 2023
Introduction Non‐inferiority of NEPA (fixed combination of NK1 receptor antagonist (RA), netupitant, and 5‐HT3RA, palonosetron) versus an aprepitant regimen was previously shown in a pragmatic study in patients receiving anthracycline cyclophosphamide ...
Laurent Zelek, Rudolph Navari, Matti Aapro, Florian Scotté   +3 more
doaj   +1 more source

Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism

, 2005
BACKGROUND: Patients receiving the highly emetogenic high-dose chemotherapy regimen with cyclophosphamide, thiotepa and carboplatin (CTC) may benefit from the neurokin-1 receptor antagonist aprepitant in addition to standard anti-emetic therapy.
van Dam, Selma M., de Jonge, Milly E., Holtkamp, Marjo J., Beijnen, Jos H., Rodenhuis, Sjoerd, Huitema, Alwin D. R.   +5 more
core   +1 more source